Home » CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer
CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer
The Centers for Medicare and Medicaid Services (CMS) announced that it will begin covering FDA approved/cleared diagnostic tests that use next generation sequencing (NGS) to detect inherited ovarian and breast cancer.
“NGS tests provide the most comprehensive genetic analysis of a patient’s cancer because they enable simultaneous detection of multiple types of genetic alterations,” said CMS Administrator Seema Verma.
The NGS diagnostics provide clinical information that can help physicians develop a personalized cancer treatment plan for each patient.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May